Ozempic for Prediabetes: Evidence, Eligibility, Coverage

Ozempic is not FDA approved for prediabetes. It is approved for type 2 diabetes, heart risk and kidney disease in type 2 diabetes. Some doctors prescribe it when one of those uses also applies. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.

Active ingredient: semaglutide
How it is taken: weekly injection
Approved for: Type 2 diabetes, heart risk and kidney disease in type 2 diabetes
Best result (STEP 1): 14.9% weight loss

Ozempic in brief

Time it stays in your body

Its half-life is about 1 week. After 7 d, half is gone, and five half-lives (35 d) leave about 3% behind.

Weight loss in the main trial

In SUSTAIN 1 over 30 weeks, weight loss was 4.7 kg, compared with 1.2 kg on placebo for type 2 diabetes.

Cost over time

Monthly prices in US dollars include the list price and self-pay offers. Each price comes from the maker's price page.

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies?

Ozempic: who qualifies
Who sets the rule	Who qualifies
FDA label	It lowers blood sugar in adults with type 2 diabetes when used with diet and exercise.
FDA label	For adults with type 2 diabetes who also have heart disease, this medicine lowers the chance of stroke, heart attack, or heart-related death.
FDA label	Adults with chronic kidney disease and type 2 diabetes get a lower risk of kidney disease worsening, kidney failure, and death tied to the heart when they take this medicine.
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	a diet and activity program for 6 months first

Sources: the FDA label (DailyMed) and aetna.com.

Trial results for prediabetes

No trial enrolled people with prediabetes alone. All participants were adults who had obesity or were overweight, and none had diabetes.

Trials that included the same ingredient (semaglutide)
Trial	Medicine	Who took part	Length	People	Main result	Comparison
STEP 1	Wegovy	Adults with obesity or overweight, without diabetes	68 weeks	1,961	14.9% weight loss	2.4% on placebo
OASIS 4	Wegovy	Adults with obesity or overweight, without diabetes	64 weeks	307	13.6% weight loss	2.4% on placebo

Trial source: STEP 1 (FDA label (DailyMed)).

What is different for prediabetes?

Ozempic: label points for prediabetes
What changes	What the label says
Hypoglycemia with Concurrent Use of Insulin Secretagogues or Insulin	Low blood sugar is more likely when you take it with insulin or a sulfonylurea, so those doses may need lowering.
Taken with insulin or sulfonylureas	The chance of low blood sugar goes up if this medicine is used with insulin or with a sulfonylurea, such as glipizide or glimepiride. The doctor may then lower those doses.

FDA labels include this information: DailyMed FDA label.

Label warnings: FDA label on DailyMed.

Coverage for prediabetes

Medicare Part D does not cover a GLP-1 when it is used only for weight loss.

You normally need prior authorization where Medicaid covers weight-loss GLP-1s.

See humana.com and KFF for the sources.

Alternatives for prediabetes

GLP-1 medicines and prediabetes
Medicine	For prediabetes	How it is taken	Trial result
Ozempic	Not a listed use	weekly injection	Not listed
Wegovy	Not a listed use	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Not a listed use	daily tablet	Not listed
Mounjaro	Not a listed use	weekly injection	Not listed
Zepbound	Not a listed use	weekly injection	20.9% weight loss
Foundayo	Not a listed use	daily tablet	11.1% weight loss
Trulicity	Not a listed use	weekly injection	Not listed
Saxenda	Not a listed use	daily injection	7.4% weight loss
Victoza	Not a listed use	daily injection	Not listed
Byetta	Not a listed use	twice-daily injection	Not listed